Table 1 Baseline demographic information for each of the treatment groups in the three analyses
From: Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease
A. Simvastatin trial re-analyses | B. Continual use of statins (trials from the integrated dataset) | C. Continual use of statins (ROS/MAP dataset) | |||||
|---|---|---|---|---|---|---|---|
Simvastatin arm | Original placebo arm | New (pooled) placebo arm | Statin users | Statin nonusers | Statin users | Statin nonusers | |
Number of subjects | 171 | 169 | 460 | 600 | 793 | 346 | 513 |
Age (mean, years)a | 73.3 ± 9.8 SD | 74.5 ± 8.9 SD | 75.0 ± 8.6 SD | 76 ± 7.5 SD | 76.7 ± 8.4 SD | 81.8 ± 6.6 SD | 82.5 ± 6.7 SD |
Gender (% female) | 57.7 | 60.5 | 58.9 | 49.8 | 59.5 | 74.3 | 69.0 |
Education (mean, years)a | 14.5 ± 2.9 | 14.2 ± 3.3 SD | 14.2 ± 3.3 SD | 14.0 ± 3.1 SD | 14.0 ± 3.1 SD | 15.9 ± 3.6 SD | 16.3 ± 3.8 SD |
Race (%)a | 91.7 white and 5.8 black or African American | 93.2 white and 5.6 black or African American | 91.2 white and 5.4 black or African American | 91.8 white and 5.7 black or African American | 89.9 white and 6.9 black or African American | 91.0 white and 7.5 black or African American | 94.9 white and 4.9 black or African American |
ApoE4 carriers (%)a | 61.8 | 55.0 | 60.2 | 66.7 | 62.1 | 37.5 | 31.8 |
Mean baseline cognitive measure | 24.2 ± 9.4 SD (ADAS-cog) | 24.0 ± 10.0 SD (ADAS-cog) | 23.9 ± 9.3 SD (ADAS-cog) | 23.5 ± 9.6 SD (ADAS-cog) | 24.9 ± 9.4 SD (ADAS-cog) | 25.3 ± 5.3 SD (MMSE) –0.5 ± 0.8 SD (global cognitive scores) | 25.4 ± 4.0 SD (MMSE) –0.55 ± 0.8 SD (global cognitive scores) |